Journal: Cancers
Article Title: Immune Checkpoint Inhibitors and Cognition in Adults with Cancer: A Scoping Review
doi: 10.3390/cancers17060928
Figure Lengend Snippet: Included Studies.
Article Snippet: Rogiers et al., 2023 [ ] Belgium/Luxembourg , n = 125 (prospectively enrolled patients) Median age-60 yr (range 29–85 yr) Female-72 Male-80 Melanoma-152 Nivolumab-152 , Longitudinal study (assessments at baseline, 9 months, 18 months—6 months post-therapy) EORTC QLQ-C30 cognitive functioning scale [ ] “ Threshold for clinical importance ” (TCI) = score < 75 [ ] , Baseline ( n = 125): EORTC QLQ-C30 cognitive functioning scale—mean 89.6 (SD +/− 19.7) [Not statistically significantly different from European reference values; European mean—84.8 (SD +/− 21.3) [ ]] 17% patients score < TCI ( n = 123) 3 months: 28% patients score < TCI ( n = 95) 18 months: 34% patients score < TCI ( n = 59) “ Although cognitive functioning mean scores remained stable, they decreased (deteriorated) and approached prespecified thresholds for MIDs (minimally important differences)” .
Techniques: Concentration Assay, Functional Assay, Control